The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000663358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
1/04/2026
Date registered
Help: Date registered
4/06/2026
Date last updated
Help: Date last updated
4/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Short-Term Changes in Children’s Eye Size with Cyan (Blue-Green) Light: A Short Trial
Scientific title
Short-Term Changes in Ocular Biometry with Cyan Light in Children: A Randomised Pilot Trial
Additional trial identifiers [1] 316925 0
CT-2026-CTN-00744-1 v1
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Myopia 341360 0
Condition category
Condition code
Eye 337431 337431 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
What is the intervention?
The intervention consists of single-vision spectacles (SVS, control treatment) and cyan light exposure (Cyan+SVS, treatment intervention) delivered via custom-designed cyan light-emitting glasses worn over the participant’s habitual single-vision spectacle (SVS) correction. This light emitting glasses were developed and validated by Chakraborty et al. (2024) in collaboration with EssilorLuxottica (Paris, France), and are designed to emit controlled cyan wavelength light (peak wavelength 500 nm, a total average irradiance of 3.0W/m² and maximum irradiance 3.10 W/m²) for ocular stimulation.

Who delivers it and their relevant expertise?
The intervention is self-administered by participants at home, under the supervision of their caregivers/parents. Participants and caregivers will receive standardised instructions and training from the research team, who have expertise in vision science, clinical research, and paediatric eye studies.

How is it delivered?
Treatment Intervention: This intervention is delivered through wearable cyan light-emitting glasses, which participants will wear at home during scheduled sessions. The glasses are worn over the participant’s habitual single-vision spectacle (SVS) correction (if applicable) while engaging in normal indoor activities.
Control treatment: The control condition is delivered through single-vision spectacles (SVS). Participants will be instructed to wear SVS during all waking hours (except during sleep or water-based activities), seven days per week, for a period of 4 weeks, and to avoid using any other forms of optical correction, including sunglasses.

How often and for how long?
Treatment intervention: Participants will be instructed to wear the glasses for two 20-minute sessions per day (total daily exposure: 40 minutes): One session in the morning (7:00–11:00 am) and another session in the afternoon (1:00–6:00 pm). The two sessions must be separated by at least 3 hours. This regimen will be followed daily (7 days per week) for 4 weeks.
Control treatment: Participants will be instructed to wear SVS during all waking hours (except during sleep or water-based activities), seven days per week, for a period of 4 weeks, and to avoid using any other forms of optical correction, including sunglasses.

Washout period: Participants will be randomly assigned to receive either treatment intervention or control intervention during the first four weeks of the study. After completing the first intervention period (weeks 1 through 4), participants will undergo a one-week washout period (week 5), after which they will undergo baseline measurements and cross over to the alternate intervention (weeks 6 through 9).

Where is it delivered?
The intervention is delivered at the participant’s home environment, allowing use during routine indoor activities.

Adherence

Adherence will be monitored using a daily logbook completed by participants and their caregivers, documenting each session of light exposure. These records will be reviewed by the research team to monitor compliance with the intervention protocol, identify any missed sessions or deviations and support ongoing safety monitoring throughout the study.
Intervention code [1] 333656 0
Prevention
Intervention code [2] 333657 0
Treatment: Devices
Description of the comparator or control
What is the comparator?
The comparator is single-vision spectacles (SVS, control treatment) worn alone (i.e., without cyan light exposure). In this two-period crossover trial, participants act as their own control by receiving both the comparator condition (SVS) and the treatment condition (cyan light + SVS) in separate study periods.

Who delivers it and their relevant expertise?
The comparator treatment is self-administered by participants, with supervision from their caregivers/parents. Participants will receive appropriate spectacle prescription and instructions will be provided by the research team with expertise in vision science and clinical research.

How is it delivered ?
The comparator is delivered as an individual, home-based intervention, where participants wear their prescribed single-vision spectacles during daily activities.

How often and for how long ?
Participants will be instructed to wear single-vision spectacles during all waking hours (except during sleep or water-based activities), 7 days per week for a 4-week period.

Where is it delivered ?
The comparator treatment is delivered in the participant’s home and usual daily environments (e.g., school, indoor and outdoor settings).

Adherence will be monitored using a daily logbook completed by participants and their caregivers, recording spectacle wear. These records will be reviewed by the research team to assess compliance and identify any protocol deviations.
Control group
Active

Outcomes
Primary outcome [1] 344958 0
Change in axial length (AL) of the eye
Timepoint [1] 344958 0
Measurements will be taken at: -Baseline (week 0) -Week 1 and week 4 (during Intervention Period 1) -Week 5 (post-washout; second baseline) -Week 6 and week 9 (during Intervention Period 2)
Primary outcome [2] 345161 0
Change in subfoveal choroidal thickness (SFCT).
Timepoint [2] 345161 0
Measurements will be taken at: -Baseline (week 0) -Week 1 and week 4 (during Intervention Period 1) -Week 5 (post-washout; second baseline) -Week 6 and week 9 (during Intervention Period 2)
Secondary outcome [1] 459914 0
Change in distance and near visual acuity will be assessed as composite secondary outcome.
Timepoint [1] 459914 0
Measurements will be taken at: Baseline (week 0), Week 1 and week 4 (during Intervention Period 1), Week 5 (post-washout; second baseline), Week 6 and week 9 (during Intervention Period 2)
Secondary outcome [2] 459915 0
Tertiary outcomes assess participant-reported experience on comfort, tolerability of the intervention, and the impact on daily activities. This is a composite tertiary outcome measure.
Timepoint [2] 459915 0
Assessments will be conducted at: Week 2 and week 4 (during Intervention Period 1) Week 7 and week 9 (during Intervention Period 2)
Secondary outcome [3] 460735 0
Change in contrast sensitivity
Timepoint [3] 460735 0
Measurements will be taken at: Baseline (week 0), Week 1 and week 4 (during Intervention Period 1), Week 5 (post-washout; second baseline), Week 6 and week 9 (during Intervention Period 2)
Secondary outcome [4] 460736 0
Tertiary outcome: Assessment of time spent on near work and outdoor activities on a typical weekday and weekend using University of Houston Near-Activity and Environment Research (UH NEAR) Survey. This is a composite tertiary outcome.
Timepoint [4] 460736 0
Assessments will be conducted at the end of the 4th and 9th weeks of the study period and will cover both weekdays and weekends relating to the preceding four weeks.
Secondary outcome [5] 462092 0
Tertiary outcomes assess participant-reported sleep condition indicator (SCI) using Sleep Condition Indicator Questionnaire
Timepoint [5] 462092 0
Assessments will be conducted at: Baseline (week 0) and week 4 (during Intervention Period 1) Baseline (week 0) and week 9 (during Intervention Period 2)
Secondary outcome [6] 462094 0
Tertiary outcomes assess participant's perception of acceptability, usability, and feasibility of the intervention
Timepoint [6] 462094 0
Assessments will be conducted at the end of the 9th weeks of the study period.

Eligibility
Key inclusion criteria
Participants will be eligible if they meet the following criteria:

-Children with myopia, defined as a spherical equivalent refractive error between -0.50 D and -6.00 D
-Currently wearing single-vision distance (SVD) spectacles
-Astigmatism: less than or equal to -1.25 dioptres cylinder (DC)
-Interocular difference in refractive error less than or equal to 1.00 D
-Best-corrected visual acuity (BCVA) of 0.00 logMAR or better
Minimum age
7 Years
Maximum age
14 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if they have:

-A history of myopia control treatment (e.g., atropine or other interventions) within the past 12 months
-A history of significant ocular injury or ocular surgery
-Strabismus or other ocular motility disorders
-Refractive error other than myopia
-Any major systemic disease
-Photosensitivity (sensitivity to bright light)
-A history of seizures
-Wear blue-light filtering lenses or photochromic single-vision spectacles

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be ensured using a web-based randomisation system, which generates the allocation sequence electronically.

Participant allocation will occur after enrolment and baseline assessment, with the sequence concealed from investigators involved in recruitment and baseline measurements. The lead investigator will access the system to assign participants according to the pre-generated randomisation sequence.

Once allocation is completed, participant identifiers and assigned intervention sequences will be securely stored and locked within the system, preventing any modification.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomisation sequence will be generated using a secure web-based computer system, providing computerised random allocation of participants to one of the two intervention sequences (Cyan+SVS first or SVS first).

The sequence is generated independently by the system and ensures that each participant has an equal probability of being assigned to either sequence. No stratification will be used in this pilot trial.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment postcode(s) [1] 45679 0
5042 - Bedford Park

Funding & Sponsors
Funding source category [1] 321520 0
Commercial sector/Industry
Name [1] 321520 0
EssilorLuxottica
Country [1] 321520 0
France
Primary sponsor type
Commercial sector/Industry
Name
EssilorLuxottica
Address
Country
France
Secondary sponsor category [1] 324286 0
University
Name [1] 324286 0
Flinders University
Address [1] 324286 0
Country [1] 324286 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320054 0
Flinders University Human Research Ethics Committee
Ethics committee address [1] 320054 0
Ethics committee country [1] 320054 0
Australia
Date submitted for ethics approval [1] 320054 0
03/02/2026
Approval date [1] 320054 0
20/03/2026
Ethics approval number [1] 320054 0
9557

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149282 0
Dr Ranjay Chakraborty
Address 149282 0
Myopia and Visual Development Lab, Caring Futures Institute, College of Nursing & Health Sciences, Flinders University, Sturt drive, Adelaide, South Australia, Australia. Post code: 5042.
Country 149282 0
Australia
Phone 149282 0
+61 08 7221 8708
Fax 149282 0
Email 149282 0
Contact person for public queries
Name 149283 0
Ranjay Chakraborty
Address 149283 0
Myopia and Visual Development Lab, Caring Futures Institute, College of Nursing & Health Sciences, Flinders University, Sturt drive, Adelaide, South Australia, Australia. Post code: 5042.
Country 149283 0
Australia
Phone 149283 0
+61 08 7221 8708
Fax 149283 0
Email 149283 0
Contact person for scientific queries
Name 149284 0
Ranjay Chakraborty
Address 149284 0
Myopia and Visual Development Lab, Caring Futures Institute, College of Nursing & Health Sciences, Flinders University, Sturt drive, Adelaide, South Australia, Australia. Post code: 5042.
Country 149284 0
Australia
Phone 149284 0
+61 08 7221 8708
Fax 149284 0
Email 149284 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: No. Individual participant data will not be shared publicly to protect participant confidentiality.



What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    Ethics approval letter.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.